TrialJournal of inherited metabolic disease2018

Olipudase alfa for treatment of acid sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months.

Melissa P Wasserstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.